Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRTC
#5778
PureTech Health plc American Depositary Shares
16.7
7
+0.72%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+0.72%
Mudança mensal
-11.69%
Mudança em 6 meses
-4.17%
Mudança anual
-5.79%
Fechamento anterior
16.6
5
Open
17.0
0
Bid
Ask
Low
16.7
7
High
17.0
0
Volume
2
Mercados
Ações
Cuidados de saúde
PRTC
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
239.42 M
1.08 B
Valuation ratios
Enterprise value
4.42 B
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
PureTech Health plc - American Depositary Shares
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.
Notícias
Deupirfenidona recebe status de medicamento órfão para doença pulmonar rara
Deupirfenidone receives orphan drug status for rare lung disease
Deupirfenidona da PureTech recebe status de medicamento órfão da FDA e UE para FPI
PureTech’s deupirfenidone receives FDA and EU orphan drug status for IPF
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PureTech CEO to present at J.P. Morgan Healthcare Conference
PureTech Health nomeia Robert Lyne como CEO permanente
PureTech Health appoints Robert Lyne as permanent CEO
PureTech fornece atualização sobre resultados da AGO após preocupações dos acionistas
PureTech provides update on AGM results following shareholder concerns
Ações da PureTech caem após reunião com FDA sobre medicamento para FPI
PureTech stock falls after FDA meeting on IPF drug